Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the safety and efficacy of Lenvatinib in patients with refractory differentiated thyroid cancer has completed. The trial was sponsored …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Eisai Pharmaceuticals India Pvt. Ltd | Conditions: Thyroid Neoplasms | Phase 4 | Status: COMPLETED